$LAB
STANDARD BIOTOOLS INC. Stock $lab

$lab Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024057213 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$37.21M	$45.54M	$25.12M
YoY Change	34.48%	81.3%	-5.23%
Cost Of Revenue	$22.30M	$21.35M	$13.00M
YoY Change	58.54%	64.31%	-8.92%
Gross Profit	$14.91M	$24.19M	$12.12M
YoY Change	9.6%	99.51%	-0.92%
Gross Profit Margin	40.07%	53.11%	48.27%
Selling, General & Admin	$37.67M	$46.94M	$22.31M
YoY Change	66.7%	110.43%	-27.75%
% of Gross Profit	252.71%	194.08%	184.0%
Research & Development	$19.22M	$15.98M	$6.409M
YoY Change	210.83%	149.34%	-27.7%
% of Gross Profit	128.94%	66.07%	52.86%
Depreciation & Amortization	$3.856M	$5.194M	$3.662M
YoY Change	6.34%	41.84%	-7.78%
% of Gross Profit	25.87%	21.47%	30.2%
Operating Expenses	$56.90M	$84.37M	$41.71M
YoY Change	83.23%	102.27%	-22.77%
Operating Profit	-$41.99M	-$60.18M	-$16.59M
YoY Change	140.63%	262.7%	-39.67%
Interest Expense	$4.444M	$5.174M	$1.117M
YoY Change	293.62%	363.21%	8.45%
% of Operating Profit
Other Income/Expense, Net	$412.0K	-$2.234M	$1.130M
YoY Change	-77.6%	-297.7%	857.63%
Pretax Income	-$45.66M	-$32.03M	-$16.58M
YoY Change	172.79%	93.18%	-78.43%
Income Tax	$55.00K	$100.0K	$300.0K
% Of Pretax Income
Net Earnings	-$45.72M	-$32.16M	-$16.84M
YoY Change	168.3%	90.92%	-77.92%
Net Earnings / Revenue	-122.88%	-70.61%	-67.05%
Basic Earnings Per Share	-$0.12	-$0.27	-$0.21
Diluted Earnings Per Share	-$0.12	-$0.27	-$0.21
COMMON SHARES
Basic Shares Outstanding	372.1M	290.1M	79.06M shares
Diluted Shares Outstanding	372.3M	294.1M	79.08M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$394.7M	$462.3M	$154.5M
YoY Change	177.37%	199.14%	415.42%
Cash & Equivalents	$269.8M	$287.1M	$113.7M
Short-Term Investments	$124.9M	$175.2M	$40.87M
Other Short-Term Assets	$10.26M	$8.912M	$3.374M
YoY Change	187.55%	164.14%	-25.8%
Inventory	$42.62M	$40.36M	$22.51M
Prepaid Expenses
Receivables	$32.44M	$36.01M	$14.50M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$480.0M	$547.6M	$194.9M
YoY Change	162.21%	180.91%	166.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$74.10M	$44.79M	$25.00M
YoY Change	202.18%	79.13%	-9.74%
Goodwill	$106.3M	$106.3M	$106.3M
YoY Change	-0.03%	-0.02%	-0.05%
Intangibles	$24.08M	$24.79M	$9.800M
YoY Change	243.97%	153.0%	-60.6%
Long-Term Investments
YoY Change
Other Assets	$20.53M	$3.673M	$2.665M
YoY Change	645.61%	37.82%	-22.64%
Total Long-Term Assets	$228.7M	$230.1M	$176.7M
YoY Change	32.38%	30.2%	-11.08%
TOTAL ASSETS
Total Short-Term Assets	$480.0M	$547.6M	$194.9M
Total Long-Term Assets	$228.7M	$230.1M	$176.7M
Total Assets	$708.7M	$777.7M	$371.7M
YoY Change	99.18%	109.24%	36.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.57M	$13.14M	$6.109M
YoY Change	106.44%	115.11%	-51.19%
Accrued Expenses	$37.78M	$30.43M	$6.878M
YoY Change	426.48%	342.43%	-9.37%
Deferred Revenue	$15.11M	$13.91M	$11.64M
YoY Change	29.34%	19.51%	-5.33%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$54.78M	$54.66M	$3.333M
YoY Change	1095.35%	1539.84%
Total Short-Term Liabilities	$123.8M	$121.6M	$43.79M
YoY Change	164.32%	177.6%	-7.18%
LONG-TERM LIABILITIES
Long-Term Debt	$299.0K	$299.0K	$61.73M
YoY Change	-99.51%	-99.52%	-38.29%
Other Long-Term Liabilities	$73.52M	$2.820M	$550.0K
YoY Change	8621.59%	412.73%	-63.19%
Total Long-Term Liabilities	$73.82M	$2.820M	$550.0K
YoY Change	8657.06%	412.73%	-63.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$123.8M	$121.6M	$43.79M
Total Long-Term Liabilities	$73.82M	$2.820M	$550.0K
Total Liabilities	$198.5M	$200.4M	$157.6M
YoY Change	25.65%	27.16%	-36.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.125B	-$1.079B	-$942.9M
YoY Change	17.15%	14.42%	16.08%
Common Stock	$389.0K	$387.0K	$80.00K
YoY Change	380.25%	383.75%	3.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$510.3M	$577.3M	-$97.15M
YoY Change
Total Liabilities & Shareholders Equity	$708.7M	$777.7M	$371.7M
YoY Change	99.18%	109.24%	36.67%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$45.72M	-$32.16M	-$16.84M
YoY Change	168.3%	90.92%	-77.92%
Depreciation, Depletion And Amortization	$3.856M	$5.194M	$3.662M
YoY Change	6.34%	41.84%	-7.78%
Cash From Operating Activities	-$39.05M	-$62.48M	-$8.485M
YoY Change	318.59%	636.31%	-45.57%
INVESTING ACTIVITIES
Capital Expenditures	$1.937M	$781.0K	$1.010M
YoY Change	131.15%	-22.67%	16.36%
Acquisitions
YoY Change
Other Investing Activities	$52.19M	$318.9M	$44.16M
YoY Change	27.41%	621.98%
Cash From Investing Activities	$50.26M	$318.1M	$43.15M
YoY Change	25.25%	637.07%	-5071.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-28.36M	-19.73M	-$2.558M
YoY Change	1260.89%	671.42%	-114.15%
NET CHANGE
Cash From Operating Activities	-39.05M	-62.48M	-$8.485M
Cash From Investing Activities	50.26M	318.1M	$43.15M
Cash From Financing Activities	-28.36M	-19.73M	-$2.558M
Net Change In Cash	-17.15M	235.8M	$32.13M
YoY Change	-159.75%	633.94%	1997.52%
FREE CASH FLOW
Cash From Operating Activities	-$39.05M	-$62.48M	-$8.485M
Capital Expenditures	$1.937M	$781.0K	$1.010M
Free Cash Flow	-$40.99M	-$63.26M	-$9.495M
YoY Change	303.14%	566.21%	-42.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001162194
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-34180
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	STANDARD BIOTOOLS INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0513190
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Tower Place
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2024Q1	dei	City Area Code CityAreaCode	650
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	266-6000
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	LAB
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	372141530
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	287057000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	175225000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	63191000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36012000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19660000
CY2024Q1	us-gaap	Inventory Net InventoryNet	40359000
CY2023Q4	us-gaap	Inventory Net InventoryNet	20533000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8912000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3127000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	547565000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	158215000
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	13262000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	0
CY2024Q1	lab	Royalty Receivable Non Current RoyaltyReceivableNonCurrent	4352000
CY2023Q4	lab	Royalty Receivable Non Current RoyaltyReceivableNonCurrent	0
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44786000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32966000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30663000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3673000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2285000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24794000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1400000
CY2024Q1	us-gaap	Goodwill Goodwill	106269000
CY2023Q4	us-gaap	Goodwill Goodwill	106317000
CY2024Q1	us-gaap	Assets Assets	777667000
CY2023Q4	us-gaap	Assets Assets	323067000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13141000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9236000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30430000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21019000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5834000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4323000
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13906000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11607000
CY2024Q1	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3587000
CY2023Q4	lab	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	3612000
CY2024Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	0
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	54656000
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	54530000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	121554000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109327000
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	299000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	569000
CY2024Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	3414000
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	841000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31108000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30374000
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	33854000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3520000
CY2024Q1	lab	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	9875000
CY2023Q4	lab	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	10755000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2820000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1065000
CY2024Q1	us-gaap	Liabilities Liabilities	200351000
CY2023Q4	us-gaap	Liabilities Liabilities	159865000
CY2024Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	256000
CY2024Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	255559000
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	311253000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9744000
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	387652000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83364000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	380400000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80232000
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	387000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	83000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1674672000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	860816000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1792000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2221000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1078923000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000752000
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7251000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3132000
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	17028000
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	5977000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	577316000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	777667000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323067000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45540000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25119000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21352000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12838000
CY2024Q1	us-gaap	Gross Profit GrossProfit	24188000
CY2023Q1	us-gaap	Gross Profit GrossProfit	12281000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15980000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6429000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46943000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21295000
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	4284000
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	1150000
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	17163000
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	84370000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	28874000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-60182000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16593000
CY2024Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	25213000
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	5174000
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	72000
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2234000
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	59000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32029000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16580000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	128000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	263000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2024Q1	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	46014000
CY2023Q1	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-78171000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16843000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294125000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294125000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79080000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79080000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	536000
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	170000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-107000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	398000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	568000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31728000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16275000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148051000
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	311253000
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-18000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-901000
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	72000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11611000
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11051000
CY2024Q1	lab	Common Stock Relinquished In Litigation Settlement CommonStockRelinquishedInLitigationSettlement	1009000
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	444219000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	577316000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-81467000
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-93000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3148000
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2466000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	568000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-97153000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2024Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	25213000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11611000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3148000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2106000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2800000
CY2024Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	3088000
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	862000
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2660000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	165000
CY2024Q1	lab	Non Cash Lease Expense NonCashLeaseExpense	1446000
CY2023Q1	lab	Non Cash Lease Expense NonCashLeaseExpense	945000
CY2024Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	655000
CY2023Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	350000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	853000
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	293000
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	55000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-686000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3027000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6329000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1087000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1409000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-955000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10284000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1835000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2496000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-754000
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1751000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	804000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1454000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4453000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	154000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62476000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8485000
CY2024Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	280033000
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	73177000
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	6836000
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	112000000
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	51000000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1010000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	318075000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	43154000
CY2024Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	8192000
CY2024Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	545000
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	11051000
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2466000
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	17000
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	92000
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	72000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19733000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2558000
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	235845000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32134000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82324000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288344000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114458000
CY2024Q1	lab	Equity Consideration Transferred In Connection With Merger EquityConsiderationTransferredInConnectionWithMerger	444219000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	190000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	232000
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	240000
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	306000
CY2023Q1	lab	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	32000
CY2024Q1	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	757000
CY2023Q1	lab	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	726000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.</span></p>
CY2024Q1	lab	Amortizes Internal Use Software Costs Using Straight Line Method AmortizesInternalUseSoftwareCostsUsingStraightLineMethod	P3Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	117354000
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2024Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	46185000
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	45498000
CY2024Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-50019000
CY2023Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-45053000
CY2024Q1	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	23900000
CY2024Q1	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	15300000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45540000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25119000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45540000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25119000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15127000
CY2024Q1	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	34189000
CY2024Q1	lab	Contract With Customer Revenue Recognized ContractWithCustomerRevenueRecognized	-5787000
CY2024Q1	lab	Contract With Customer Revenue Recognized Net ContractWithCustomerRevenueRecognizedNet	4231000
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	47760000
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	10722000
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6989000
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3239000
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1552000
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	22502000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	142736000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	117942000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	24794000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115954000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1400000
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2800000
CY2024Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2024Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2159000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2865000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2865000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2865000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2865000
CY2024Q1	lab	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	11175000
CY2024Q1	lab	Finite Lived Intangible Assets Future Expected Amortization Expense FiniteLivedIntangibleAssetsFutureExpectedAmortizationExpense	24794000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	287057000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51704000
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1287000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	795000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288344000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52499000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1300000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000
CY2024Q1	lab	Trade Receivables TradeReceivables	32181000
CY2023Q4	lab	Trade Receivables TradeReceivables	19972000
CY2024Q1	lab	Royalty Receivable Current RoyaltyReceivableCurrent	4319000
CY2024Q1	lab	Allowance For Expected Credit Losses AllowanceForExpectedCreditLosses	-488000
CY2023Q4	lab	Allowance For Expected Credit Losses AllowanceForExpectedCreditLosses	-312000
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	36012000
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	19660000
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	42371000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12140000
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	655000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	282000
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10595000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8111000
CY2024Q1	us-gaap	Inventory Gross InventoryGross	53621000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	20533000
CY2024Q1	lab	Inventory Current InventoryCurrent	40359000
CY2023Q4	lab	Inventory Current InventoryCurrent	20533000
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	13262000
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	400000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	102803000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	57342000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	62831000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35489000
CY2024Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	4814000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2334000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44786000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24187000
CY2024Q1	us-gaap	Depreciation Depreciation	3000000
CY2023Q1	us-gaap	Depreciation Depreciation	700000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11603000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12052000
CY2024Q1	lab	Loss Contingency Accruals LossContingencyAccruals	4516000
CY2024Q1	lab	Accrued Warranties Current AccruedWarrantiesCurrent	2444000
CY2023Q4	lab	Accrued Warranties Current AccruedWarrantiesCurrent	2593000
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3166000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	825000
CY2024Q1	lab	Accrued Uninvoiced Receipts Current AccruedUninvoicedReceiptsCurrent	2764000
CY2023Q4	lab	Accrued Uninvoiced Receipts Current AccruedUninvoicedReceiptsCurrent	1516000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5937000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4033000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30430000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21019000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Maximum Contract Value ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue	34000000
CY2020Q3	lab	Research And Development Arrangement Contract To Perform For Others Capital Expenditures ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures	22200000
CY2024Q1	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	900000
CY2023Q1	lab	Research And Development Arrangement Contract To Perform For Others Depreciation Expense ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense	900000
CY2024Q1	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	8700000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses	7800000
CY2024Q1	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	13500000
CY2023Q4	lab	Research And Development Arrangement Contract To Perform For Others Property And Equipment Net ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet	14400000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	54955000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	63513000
CY2024Q1	lab	Number Of Leases For Office And Laboratory Space NumberOfLeasesForOfficeAndLaboratorySpace	3
CY2024Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	extend the leases
CY2024Q1	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2556000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2010000
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1195000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	765000
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	1076000
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	921000
CY2024Q1	us-gaap	Lease Cost LeaseCost	2675000
CY2023Q1	us-gaap	Lease Cost LeaseCost	1854000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	7361000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9686000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8721000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7388000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7355000
CY2024Q1	lab	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	10224000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	50735000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13793000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	36942000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5834000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31108000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2024Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	21600000
CY2024Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	2300000
CY2024Q1	lab	Purchase Commitment Agreement PurchaseCommitmentAgreement	6900000
CY2024Q1	lab	Settlement Of Outstanding Litigation SettlementOfOutstandingLitigation	6200000
CY2024Q1	lab	Repurchase Of Common Stock Shares For Litigation Settlement RepurchaseOfCommonStockSharesForLitigationSettlement	1850000
CY2024Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	6200000
CY2024Q1	lab	Settled Outstanding Litigation SettledOutstandingLitigation	422048
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	199635000
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	32000
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	199603000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	98554000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	98576000
CY2024Q1	us-gaap	Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	906
CY2024Q1	lab	Change In Fair Value Of Warrant Liabilities Recurring Basis ChangeInFairValueOfWarrantLiabilitiesRecurringBasis	853
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1759
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	21181000
CY2024Q1	lab	Stock Based Compensation Expense Due To Acceleration Of Awards StockBasedCompensationExpenseDueToAccelerationOfAwards	6200000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9294
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.62
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2024Q1	lab	Stock Options Assumed Through Acquisition StockOptionsAssumedThroughAcquisition	28184
CY2024Q1	lab	Stock Options Assumed Weighted Average Exercise Price StockOptionsAssumedWeightedAverageExercisePrice	4.8
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	300
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.25
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	53
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.79
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	583
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.44
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	37142
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.5
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2965
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	25933
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	4.93
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne	P7Y2M12D
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue	396
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	11209
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	3.5
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1	P8Y7M6D
CY2024Q1	lab	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	2569
CY2024Q1	us-gaap	Share Price SharePrice	2.71
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11611
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3148000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-32157000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16843000
CY2024Q1	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	46014000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-78171000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16843000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294125000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294125000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79080000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79080000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	46021000
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14624000
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	75164000
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	11692000
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	76684000
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	108764000
CY2024Q1	lab	Number Of Additional Shares Issuable Under Make Whole Premium Maximum NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum	4741374
CY2024Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	4119486
CY2023Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1250484
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45540000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25119000
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	4284000
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	1150000
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	17163000
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-60182000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16593000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5194000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3662000
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	4300000
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	1200000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	825000
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	4284000
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1943000
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	3166000
CY2024Q1	us-gaap	Restructuring Charges RestructuringCharges	4284000
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	1150000
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	46465458
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	lab	Rule10 B51 Arr Modified Flag Rule10B51ArrModifiedFlag	false
CY2024Q1	lab	Non Rule10 B51 Arr Modified Flag NonRule10B51ArrModifiedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
lab-20240331_htm.xml	Edgar Link	completed
0000950170-24-057213-index-headers.html	Edgar Link	pending
0000950170-24-057213-index.html	Edgar Link	pending
0000950170-24-057213.txt	Edgar Link	pending
0000950170-24-057213-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img187292897_0.jpg	Edgar Link	pending
lab-20240331.htm	Edgar Link	pending
lab-20240331.xsd	Edgar Link	pending
lab-ex31_1.htm	Edgar Link	pending
lab-ex31_2.htm	Edgar Link	pending
lab-ex32_1.htm	Edgar Link	pending
lab-ex32_2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LAB
STANDARD BIOTOOLS INC. Stock $lab

2024 Q2 Form 10-Q Financial Statement

#000095017024057213 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB STANDARD BIOTOOLS INC. Stock $lab

2024 Q2 Form 10-Q Financial Statement

#000095017024057213 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB
STANDARD BIOTOOLS INC. Stock $lab